Abemaciclib
- Generic Name
- Abemaciclib
- Brand Names
- Verzenio, Verzenios
- Drug Type
- Small Molecule
- Chemical Formula
- C27H32F2N8
- CAS Number
- 1231929-97-7
- Unique Ingredient Identifier
- 60UAB198HK
- Background
Abemaciclib is an antitumor agent and dual inhibitor of cyclin-dependent kinases 4 (CDK4) and 6 (CDK6) that are involved in the cell cycle and promotion of cancer cell growth in case of unregulated activity. On September 28, 2017, FDA granted approval of abemaciclib treatment under the market name Verzenio for the treatment of HR-positive and HER2-negative a...
- Indication
适应症为:⑴单药治疗接受过内分泌疗法和化疗后疾病进展的 ER+/HER2-晚期或转移性乳腺癌；⑵或联合氟维司群，二线治疗接受过内分泌疗法后疾病进展的 ER+/HER2-晚期或转移性乳腺癌；⑶联合芳香酶抑制剂作为 ER+/HER2-绝经后女性晚期或转移性乳腺癌的初始内分泌疗法。
- Associated Conditions
- HR+, HER2-, Advanced Breast Cancer, Early Hormone Receptor Positive, HER2/Neu Negative Node Positive Breast Cancer, Metastatic HR + HER2 - breast cancer
- Associated Therapies
- -
A Study of Abemaciclib and Radiation Therapy in People With Metastatic Breast Cancer
- First Posted Date
- 2024-11-07
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 28
- Registration Number
- NCT06678269
- Locations
- 🇺🇸
Memorial Sloan Kettering at Basking Ridge (All protocol activities), Basking Ridge, New Jersey, United States
🇺🇸Memorial Sloan Kettering Monmouth (All Protocol Activities), Middletown, New Jersey, United States
🇺🇸Memorial Sloan Kettering Bergen (All Protocol Activities), Montvale, New Jersey, United States
Testing the Addition of an Anti-Cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (5-Fluorouracil) for Metastatic, Refractory Colorectal Cancer
- First Posted Date
- 2024-10-23
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 39
- Registration Number
- NCT06654037
A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer
- Conditions
- Advanced Breast CarcinomaAdvanced Malignant Solid NeoplasmAdvanced Ovarian CarcinomaAdvanced Pancreatic CarcinomaAdvanced Prostate CarcinomaAdvanced SarcomaAnatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Stage III Ovarian Cancer AJCC v8Stage III Pancreatic Cancer AJCC v8
- Interventions
- Drug: AbemaciclibProcedure: BiopsyProcedure: Biospecimen CollectionDrug: FulvestrantProcedure: Bone ScanDrug: CarboplatinDrug: OlaparibProcedure: EchocardiographyDrug: GemcitabineDrug: PemetrexedDrug: ExemestaneDrug: LetrozoleDrug: GefitinibProcedure: Multigated Acquisition ScanOther: Survey AdministrationDrug: TamoxifenDrug: TemozolomideDrug: PaclitaxelDrug: OsimertinibDrug: Pegylated Liposomal Doxorubicin Hydrochloride
- First Posted Date
- 2024-10-08
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 30
- Registration Number
- NCT06630325
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
ONO-4578-06:Phase I Study of ONO-4578 and Letrozole Plus CDK4 /6 Inhibitors in Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-08-26
- Last Posted Date
- 2024-08-26
- Lead Sponsor
- Ono Pharmaceutical Co. Ltd
- Target Recruit Count
- 46
- Registration Number
- NCT06570031
- Locations
- 🇯🇵
Saitama Cancer Center, Ina, Saitama, Japan
🇯🇵Tokyo Medical University Hospital, Shinjuku-ku, Tokyo, Japan
🇯🇵National Cancer Center Hospital East, Kashiwa-shi, Chiba, Japan
Precision Treatment of HR+ HER2- Advanced Breast Cancer Based on SNF Molecular Subtyping
- Conditions
- Interventions
- First Posted Date
- 2024-08-19
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 260
- Registration Number
- NCT06561022
- Locations
- 🇨🇳
270 Dongan Road, Fudan University Shanghai Cancer Center, Shanghai, China
Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue Sarcoma
- Conditions
- Interventions
- First Posted Date
- 2024-07-12
- Last Posted Date
- 2024-10-11
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 70
- Registration Number
- NCT06498648
A Real-life Study to Understand the Use and Effects of Palbociclib in US Patients With Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-07-10
- Last Posted Date
- 2024-07-10
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 5087
- Registration Number
- NCT06495164
- Locations
- 🇺🇸
Pfizer New York, New York, New York, United States
A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following Radiotherapy
- First Posted Date
- 2024-05-14
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 45
- Registration Number
- NCT06413706
- Locations
- 🇧🇪
Centre Hospitalier Regional de la Citadelle, Liege, Belgium
🇺🇸Phoenix Children's Hospital, Phoenix, Arizona, United States
🇺🇸Children's Hospital of Orange County, Orange, California, United States
Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-05-10
- Last Posted Date
- 2024-10-01
- Target Recruit Count
- 15
- Registration Number
- NCT06409390
- Locations
- 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer
- First Posted Date
- 2024-04-24
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 500
- Registration Number
- NCT06380751
- Locations
- 🇬🇧
Research Site, Taunton, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.